Are there long-term benefits of donepezil in Alzheimer's disease?

CMAJ. Canadian Medical Association Journal

Volumn 171, Issue 10, 2004, Pages 1174-1175

  Black, Sandra E ^a   Szalai, John P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL;

ALZHEIMER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOTE; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 8744289427     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1041615     Document Type: Note

References (3)

1. Lanctôt KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169(6): 557-64.
2. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57(3):481-8.
3. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004;61:252-6.